Repligen | RGEN - Interest Expense On Debt


Repligen reported $5.58M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Agilent USD 25M 2M Dec/2025
Align Technology USD 16.04M 14.04M Dec/2025
Bio Techne USD 2.17M 9K Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
Bruker USD 8.1M 11.9M Dec/2025
Charles River Laboratories USD 26.74M 2.97M Mar/2026
Danaher USD 63M 8M Mar/2026
Dentsply International USD 24M 2M Mar/2026
General Electric Aerospace USD 496M 271M Dec/2025
Henry Schein USD 39M 0 Mar/2026
Illumina USD 26M 1000K Dec/2025
IQVIA Holdings USD 192M 1000K Mar/2026
Mettler Toledo International USD 17.39M 307K Dec/2025
Myriad Genetics USD 4.4M 600K Dec/2025
OraSure Technologies 1.67M 1.13M Dec/2025
Pacific Biosciences Of California USD 1.74M 1000 Dec/2025
Pfizer USD 671M 40M Mar/2026
Repligen USD 5.58M 83K Mar/2026
Revvity USD 24.72M 1.2M Mar/2026
Standard Biotools USD 5K 5K Dec/2025
Thermo Fisher Scientific USD 354M 11M Mar/2026
Waters USD 42M 33.38M Mar/2026
West Pharmaceutical Services USD 1.9M 1.7M Mar/2026